@article{elliott_linder_nolan_2020, title={Feasibility study evaluating arrhythmogenesis and cardiac damage after heart-base irradiation in mice: A brief communication}, volume={6}, ISSN={["2053-1095"]}, DOI={10.1002/vms3.303}, abstractNote={Abstract}, number={4}, journal={VETERINARY MEDICINE AND SCIENCE}, author={Elliott, James and Linder, Keith and Nolan, Michael W.}, year={2020}, month={Nov}, pages={1009–1016} }
 @article{purzycka_peters_elliott_lamb_priestnall_hardas_johnston_rodriguez-piza_2020, title={Histiocytic sarcoma in miniature schnauzers: 30 cases}, volume={61}, ISSN={["1748-5827"]}, DOI={10.1111/jsap.13139}, abstractNote={ObjectivesTo summarise the clinical presentation and outcomes in a series of miniature schnauzers diagnosed with histiocytic sarcoma.}, number={6}, journal={JOURNAL OF SMALL ANIMAL PRACTICE}, author={Purzycka, K. and Peters, L. M. and Elliott, J. and Lamb, C. R. and Priestnall, S. L. and Hardas, A. and Johnston, C. A. and Rodriguez-Piza, I.}, year={2020}, month={Jun}, pages={338–345} }
 @article{llanos_lara_elliott_2020, title={Primary tonsillar histiocytic sarcoma in two dogs}, volume={8}, ISSN={["2052-6121"]}, DOI={10.1136/vetreccr-2020-001106}, abstractNote={SUMMARY}, number={3}, journal={VETERINARY RECORD CASE REPORTS}, author={Llanos, Cesar and Lara, Ana and Elliott, James}, year={2020}, month={Sep} }
 @article{elliott_looper_keyerleber_turek_blackwood_henry_gieger_2020, title={Response and outcome following radiation therapy of macroscopic canine plasma cell tumours}, volume={18}, ISSN={["1476-5829"]}, DOI={10.1111/vco.12600}, abstractNote={Abstract}, number={4}, journal={VETERINARY AND COMPARATIVE ONCOLOGY}, author={Elliott, James and Looper, Jayme and Keyerleber, Michele and Turek, Michelle and Blackwood, Laura and Henry, Joshua and Gieger, Tracy}, year={2020}, month={Dec}, pages={718–726} }
 @article{elliott_baines_2019, title={A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017)}, volume={97}, ISSN={["1751-0813"]}, DOI={10.1111/avj.12847}, abstractNote={Multi‐agent chemotherapy (vincristine, epirubicin and prednisolone) including either cyclophosphamide (CEOP) or lomustine (LEOP) was given as first‐line chemotherapy to treatment‐naïve canine lymphoma patients with measurable, high grade T‐cell lymphoma (HGTCL). All patients responded to either CEOP or LEOP. Toxicity was typical of multi‐agent chemotherapy protocols and 25% of dogs receiving lomustine exhibited mild‐to‐moderate ALT elevation and 29% grade 3 or 4 neutropenia. Median progression‐free survival (100 versus 269 days) and overall survival (155 versus 327 days) were significantly higher in patients receiving LEOP compared to CEOP. Overall survival was improved for patients receiving LEOP compared to those receiving CEOP followed by lomustine‐based rescue therapy. The results of this retrospective study support further evaluation of lomustine as part of first‐line, multi‐agent therapy for patients with HGTCL.}, number={9}, journal={AUSTRALIAN VETERINARY JOURNAL}, author={Elliott, J. and Baines, S.}, year={2019}, month={Sep}, pages={308–315} }
 @article{smallwood_tanis_grant_blackwood_killick_amores-fuster_elliott_mas_harper_marrington_et al._2019, title={Evaluation of a multi-agent chemotherapy protocol combining dexamethasone, melphalan, actinomycin D, and cytarabine for the treatment of resistant canine non-Hodgkin high-grade lymphomas: a single centre's experience}, volume={17}, ISSN={["1476-5829"]}, DOI={10.1111/vco.12457}, abstractNote={The DMAC protocol (dexamethasone, melphalan, actinomycin‐D, cytarabine) has been evaluated in American studies for the treatment of relapsed canine lymphoma, comparing similarly to other rescue protocols. The aim of this study was to evaluate efficacy and toxicity of DMAC, in a larger UK cohort of resistant canine lymphomas. Medical records of dogs with resistant non‐Hodgkin high‐grade lymphomas that received DMAC as a rescue protocol were reviewed from 2007 to 2017. Response, time from initiation to discontinuation (TTD) and toxicity (Veterinary Cooperative Oncology Group criteria) were assessed. One hundred dogs were included; 86 received CEOP (modified CHOP including epirubicin) as first‐line treatment. Thirty‐five dogs (35%) responded: 21 complete responders (CRs) and 14 partial responders (PRs). Responders had significantly longer TTD (P < 0.001) compared with non‐responders: 62 days (range 28‐952) for CR vs 32 days (range 20‐70) for PR. Six CR received more than six cycles of DMAC (range 7‐36 cycles) and experienced a longer TTD (median 508, range 126‐952 days). Thrombocytopenia occurred in 45% (24 grade 1‐2, 21 grade 3‐4) and neutropenia in 36% of cases (29 grade 1‐2, 7 grade 3‐4). Gastrointestinal toxicity occurred in 42% of dogs (40 grade 1‐2, 2 grade 3‐4). Owing to chemotherapy toxicity, treatment was discontinued in five, and hospitalization required in six cases. In this study, response to DMAC was lower and of generally shorter duration than previously reported. Toxicity was high, but infrequently led to hospitalization or discontinuation of treatment.}, number={2}, journal={VETERINARY AND COMPARATIVE ONCOLOGY}, author={Smallwood, Katherine and Tanis, Jean-Benoit and Grant, Iain A. and Blackwood, Laura and Killick, David R. and Amores-Fuster, Isabel and Elliott, James and Mas, Aran and Harper, Aaron and Marrington, Mary and et al.}, year={2019}, month={Jun}, pages={165–173} }
 @article{elliott_alderson_2019, title={Managing cancer pain in dogs and cats}, volume={41}, ISSN={["2042-7689"]}, DOI={10.1136/inp.l5486}, abstractNote={Background: Cancer is a frequent diagnosis in modern veterinary medicine, and one of the most common causes of mortality.}, number={8}, journal={IN PRACTICE}, author={Elliott, James and Alderson, Briony}, year={2019}, month={Oct}, pages={361–367} }
 @article{elliott_2019, title={Response and outcome following toceranib phosphate treatment for stage four anal sac apocrine gland adenocarcinoma in dogs: 15 cases (2013-2017)}, volume={254}, ISSN={["1943-569X"]}, DOI={10.2460/javma.254.8.960}, abstractNote={Abstract}, number={8}, journal={JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION}, author={Elliott, James W.}, year={2019}, month={Apr}, pages={960–966} }
 @misc{elliott_alderson_2019, title={Should we be euthanasing cancer patients?}, volume={185}, ISSN={["2042-7670"]}, DOI={10.1136/vr.l6239}, abstractNote={It was great to read that the article we recently published ‘Managing cancer pain in cats and dogs’, in October’s In Practice , is being read. But we worry, given Peter Clark’s comment ( VR , 26 October 2019, vol 185, p 514), that the article’s message has been taken out of context.

The aim of the article was to review cancer pain in dogs and …}, number={17}, journal={VETERINARY RECORD}, author={Elliott, James and Alderson, Briony}, year={2019}, month={Nov} }
 @article{elliott_2018, title={Lomustine chemotherapy for the treatment of presumptive haemophagocytic histiocytic sarcoma in Flat-coated Retrievers}, volume={96}, ISSN={["1751-0813"]}, DOI={10.1111/avj.12767}, abstractNote={BackgroundThe Flat‐coated Retriever (FCR) is a breed at‐risk for histiocytic sarcoma (HS). A haemophagocytic form of HS (HPHS) occurs in the spleen ± other sites such as bone marrow, and is a CD11d+ disease of macrophage origin. Patients with HPHS typically present with regenerative anaemia. Lomustine is a well‐accepted, first‐line chemotherapy for dogs with HS, but its specific utility in dogs with HPHS has not been previously reported.}, number={12}, journal={AUSTRALIAN VETERINARY JOURNAL}, author={Elliott, J.}, year={2018}, month={Dec}, pages={502–507} }